| Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript |
Journey Medical Corporation (NASDAQ:DERM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srinivas Sidgiddi - Vice President, Research and Development Ramsey Alloush - Chief Operating Officer and General Counsel Conference Call Participants Scott Henry - AGP Kalpit Patel - B. Riley Securities Thomas Flatten - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-14 23:08:30 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates |
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago. |
zacks.com |
2025-05-14 22:10:35 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 |
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? |
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-23 12:00:39 |
Czytaj oryginał (ang.) |
| Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? |
Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-07 14:46:53 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer |
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”). Mr. Alloush will continue to also serve as the Company's General Counsel. |
globenewswire.com |
2025-04-01 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript |
Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-03-26 21:10:04 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates |
Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share a year ago. |
zacks.com |
2025-03-26 20:15:39 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights |
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz. |
globenewswire.com |
2025-03-26 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea |
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults. |
globenewswire.com |
2025-03-24 10:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 |
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the 37th Annual ROTH Conference |
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California. |
globenewswire.com |
2025-03-12 10:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea |
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks |
globenewswire.com |
2025-03-05 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida |
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 |
globenewswire.com |
2025-03-04 18:01:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's January 2025 New Analysts |
In January, Seeking Alpha welcomed 29 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Conservative Investor recommending Dassault Aviation, Christopher Gray on ASML Holding, and Inflexio Research on Bragg Gaming Group, all rated as Buys. Analysts' diverse backgrounds span sectors like technology, finance, and consumer staples, with investment strategies focusing on value, growth, and special situations. |
seekingalpha.com |
2025-02-05 10:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point |
Journey Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need for additional funding, Emrosi's market exclusivity until 2039 and strong trial results offer significant potential. Dermatologists' acceptance and PBM positioning are crucial for Emrosi's success, given its proven efficacy and potential to replace Oracea. |
seekingalpha.com |
2025-01-30 11:18:33 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea |
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. |
globenewswire.com |
2025-01-23 10:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates |
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.80 per share a year ago. |
zacks.com |
2024-11-12 20:26:09 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights |
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock? |
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-11-04 10:21:09 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea |
Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. |
globenewswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference |
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects |
globenewswire.com |
2024-10-25 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference |
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City. |
globenewswire.com |
2024-10-03 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference |
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference, scheduled to take place on Thursday, September 12, 2024 in New York City. |
globenewswire.com |
2024-09-09 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference. |
globenewswire.com |
2024-09-04 12:15:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript |
Journey Medical Corporation (NASDAQ:DERM ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Kalpit Patel - B. Riley Securities Scott Henry - Alliance Global Partners Jason Wittes - Roth Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-08-12 23:37:05 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates |
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-08-12 22:10:59 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights |
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz. |
globenewswire.com |
2024-08-12 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 |
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET |
globenewswire.com |
2024-08-06 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors |
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. |
globenewswire.com |
2024-07-11 20:05:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase |
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET. |
globenewswire.com |
2024-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript |
Journey Medical Corporation (NASDAQ:DERM ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim Chief Financial Officer Dr. Srinivas Sidgiddi - Vice President, Research and Development Ramsey Allous - General Counsel and Corporate Secretary Conference Call Participants Scott Henry - Alliance Global Partner Kalpit - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-05-14 02:43:09 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights |
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz. |
globenewswire.com |
2024-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 |
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET |
globenewswire.com |
2024-05-07 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer |
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. |
globenewswire.com |
2024-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 |
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2024. The conference is being held on April 30 – May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV. |
globenewswire.com |
2024-04-25 12:30:00 |
Czytaj oryginał (ang.) |
| Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript |
Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript |
seekingalpha.com |
2024-03-21 22:22:02 |
Czytaj oryginał (ang.) |